As 2022 draws to a close, on behalf of the National Foundation for Infectious Diseases (NFID), we are grateful to all of our partners and donors whose generous support helps make our work possible. 2022 was another banner year during which we achieved:
- 4B+ media impressions from the NFID Influenza/Pneumococcal Disease News Conference
- Professional education of 15,000+ individuals from 86 countries
- 23 educational activities (webinars, courses, and conferences)
- 200+ collaborating partners
Collaboration is a core value for NFID and is a central tenet of our efforts to speak with ‘one strong voice’ in support of evidence-based approaches to the effective prevention and treatment of infectious diseases across the lifespan. NFID could not do this important work without the support of our partners, donors, and stakeholders. Join us as we reflect and celebrate the powerful impact of our collective voices, as highlighted in the NFID FY22 Annual Report:
Download a copy of the Annual Report at: www.nfid.org/annual-report
Your Support Makes a Difference
We are extremely grateful to those who have donated to NFID this year, and we look forward to continued collaboration and building on the momentum of our accomplishments as we celebrate the 50th anniversary of NFID in 2023, with an updated strategic plan.
If you have not yet made a contribution, there is still time to join the fight against infectious diseases through an online donation. From all of us at NFID, thank you for your continued support!
We wish you the gift of health this holiday season and throughout the coming year …
To join the conversation and get the latest news on infectious diseases, follow NFID on Twitter, like us on Facebook, follow us on Instagram, visit us on LinkedIn, listen to the Infectious IDeas podcast, and subscribe to receive future NFID Updates.
Related Posts
Protecting the Health of Black Children
Failure to understand the history of vaccine-preventable diseases risks dooming US children to again suffer needlessly from preventable infections
Advancing Prevention in a Complex Respiratory Season
2025–2026 Respiratory Campaign round-up: NFID and partners urge immunization to help protect against COVID-19, flu, RSV, and pneumococcal disease
There’s Nothing New About Applying a ‘Gold Standard’ to Vaccine Trials
How vaccine clinical trials work—and the true “gold standard” for safety, effectiveness, and ethics

